Actinium Pharmaceuticals Hosts Webinar on ATNM-400 Prostate Cancer Therapy

PUBT · 2d ago
Actinium Pharmaceuticals Hosts Webinar on ATNM-400 Prostate Cancer Therapy
  • Actinium Pharmaceuticals will host a webinar on its investigational HER3-targeted radiotherapy ATNM-400 on December 1, 2026, at 8 a.m. ET.
  • Management will review initial Phase 1 prostate cancer findings and discuss the RADIANZ imaging study assessing potential across tumor types.
  • Memorial Sloan Kettering Cancer Center's Michael J. Morris will discuss metastatic castration-resistant prostate cancer treatment needs beyond PSMA-directed therapies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611120800PR_NEWS_USPR_____NY96018) on November 12, 2026, and is solely responsible for the information contained therein.